A study looking at the long term follow up of people who have taken aspirin and esomeprazole to help prevent oesophageal cancer (AspECT Excel)

Cancer type:

Oesophageal cancer

Status:

Open

Phase:

Other

This study is looking at the long term benefits and risks of taking aspirin and esomeprazole to help prevent oesophageal cancer. It is a continuation of the AspECT trial. 

It is open to people who took part in the AspECT trial. 

Cancer Research UK supports this study.

More about this trial

The AspECT trial looked at aspirin and esomeprazole to see whether it could reduce the risk of oesophageal cancer for people with Barrett’s oesophagus. 

In this trial there were 4 groups. It was a randomised trial Open a glossary item. People were put into one of the following at random:

  • a low dose of esomeprazole and no aspirin
  • a high dose of esomeprazole and no aspirin
  • a low dose of esomeprazole and aspirin
  • a high dose of esomeprazole and aspirin

The results of the AspECT trial showed that high doses of esomeprazole by itself reduced the risk of oesophageal cancer. It also showed that the combination of high dose of esomeprazole and aspirin might be better than high dose esomeprazole by itself. 

In this study the team will look at your medical records over a long period of time. 

The team think the results of this study could change the national guidelines about how best to prevent Barrett’s oesophagus developing into cancer.  

The aims are to find out:

  • how well the combination of high dose esomeprazole and aspirin works to prevent oesophageal cancer in the longer term 
  • more about the side effects 

Who can enter

Who can take part

You may be able to join this study if you took part in the AspECT trial and you agree that the study team can look at your medical records.

Trial design

This is a phase 4 study. The team are looking at a maximum of 1,587 people to take part. 

The study team will collect information from your medical and NHS records. This will include:

  • personal information such as your date of birth
  • information about your participation in the AspECT trial
  • information about your health such as your Barrett’s oesophagus, other medical conditions, treatments and hospital visits

You don’t have any further treatment as part of this study.

Hospital visits

There are no hospital visits.

Side effects

There are no side effects.

Location

Aberystwyth
Chester
Croydon
Derby
Edinburgh
Glasgow
Gloucester
Harrogate
Kirkcaldy
Leicester
Liverpool
London
Nottingham
Portsmouth
Taunton
Torbay
Truro
West Bromwich
Yeovil

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Janusz Jankowski

Supported by

Cancer Research UK
University College London (UCL)

Other information

This is Cancer Research UK trial number is CRUK/21/020.

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

19401

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think